DNV001 not checked
Hangzhou Dinovate Biotech Co., Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “DNV001 is a human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), administered as a sterile solution for subcutaneous injection. It is supplied in a 1.5 mL type I borosilicate glass vial with a concentration of 200 mg/mL (300 mg per vial). The product should be stored at or below 25°C and must not be frozen”In the company’s words, NCT07391722 on ClinicalTrials.gov
- Tested for
- Primary Hypercholesterolemia
- Main trialPhase 2
- “This is a Phase II clinical study to evaluate the effectiveness and safety of different doses of DNV001 injection in patients with primary hypercholesterolemia or mixed dyslipidemia who have not achieved adequate control of low-density lipoprotein cholesterol (LDL-C) despite statin therapy. The study will enroll approximately 120 participants and will be conducted at 10-15 centers in China. Participants will be randomly assigned to one of four dose groups (50 mg, 150 mg, 300 mg-1, or 300 mg-2) or placebo, administered as subcutaneous injections. The study includes a 2-week screening period,…”In the company’s words, NCT07391722 on ClinicalTrials.gov
Other drugs for Primary Hypercholesterolemia
- ObicetrapibNewAmsterdam Pharma · Phase 3
- Laroprovstat/rosuvastatinAstraZeneca · Phase 3
- LaroprovstatAstraZeneca · Phase 3
- FDC laroprovstat/RosuvastatinAstraZeneca · Phase 3
- EnlicitideMerck & Co. · Phase 3
- Bempedoic acid/ezetimibeDaiichi Sankyo · Phase 3
Coming up1
- 30 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 30 Jun 2027 | DNV001 Injection in Patients With Hypercholesterolemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026